Naprod Life Sciences has received renewal of its Good Manufacturing Practice (GMP) certification from Brazil’s health regulator, ANVISA, for its Tarapur manufacturing facility in Maharashtra. The renewal follows a successful regulatory inspection conducted in July 2025, with no critical observations, highlighting the company’s compliance with stringent global quality and manufacturing standards.

The Tarapur facility is an integrated site with capabilities in oncology injectables, including liquid and lyophilised formulations, as well as oral solid dosage forms. The renewed certification enables Naprod to continue supplying products to Brazil, one of the largest pharmaceutical markets in Latin America.

The ANVISA GMP renewal further strengthens Naprod Life Sciences’ global regulatory profile, complementing its existing EU-GMP, PIC/S and WHO-GMP approvals. This milestone supports the company’s strategy to expand its presence in regulated international markets, deepen partnerships, and accelerate product commercialisation.

Commenting on the development, the company said the certification reflects its continued focus on quality excellence, regulatory compliance, and delivering high-quality oncology and specialty medicines to global partners and patients.